https://www.selleckchem.com/products/azd9291.html
Eight patients with stage II tumors, exclusively from the RFA group, survived for more than 3years. Clinical success was comparable between the two groups (96% vs. 100%, P=0.231). Early adverse events between the two groups were similar (10% vs. 2.9%, P=0.206); however, late biliary/pancreatic stenoses occurred in three RFA patients who were successfully managed with endoscopic interventions. Endoscopic RFA appears to prolong patients' survival with acceptable safety; it may therefore be a feasible treatment option for patients with ino
Mi piace
Commento
Condividi
